Oppenheimer Reiterates Outperform Rating on Protera Therapeutics (TARA)

November 20, 2025 6:02 AM EST Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $25.00 price target on Protera Therapeutics (NASDAQ: TARA).The analyst commented: "Protara ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login